<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Lederman, Lynne</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Schmoll, Hans-Joachim</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">No Benefit to Adding Oxaliplatin to Capecitabine in Locally Advanced Rectal Adenocarcinoma</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-15</style></pages><abstract><style  face="normal" font="default" size="100%">Treatment options for locally advanced rectal cancer include chemotherapy, surgery, and radiation therapy. It is not known if adding oxaliplatin to capecitabine would increase the efficacy of chemotherapy for patients with locally advanced rectal cancer. This article reports the disease-free survival (DFS) results from the interim analysis of Chemotherapy and Radiation Therapy Before Surgery Followed by Capecitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced Rectal Cancer [PETACC-6; NCT00766155].</style></abstract><number><style face="normal" font="default" size="100%">22</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>